...
首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers
【24h】

Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers

机译:Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers

获取原文
获取原文并翻译 | 示例
           

摘要

Discovery of cancer genes through interrogation of genomic dosage is one of the major approaches in cancer research. In this study, we report that phosphodiesterase subtype 4D(PDE4D) gene was homozygously deleted in 198 cases of 5,569 primary solid tumors (3.56), with most being internal microdeletions. Unexpectedly, the microdeletions did not result in loss of their gene products. Screening PDE4D expression in 11 different types of primary tumor samples (n = 165) with immunohistochemistry staining revealed that its protein levels were up-regulated compared with corresponding nontransformed tissues. Importantly, depletion of endogenous PDE4D with three independent shRNAs caused apoptosis and growth inhibition in multiple types of cancer cells, including breast, lung, ovary, endometrium, gastric, and melanoma, which could be rescued by reexpression of PDE4D. We further showed that antitumor events triggered by PDE4D suppression were lineage-dependently associated with Bcl-2 interacting mediator of cell death (BIM) induction and microphthalmia-associated transcription factor (MITF) downregulation. Furthermore, ectopic expression of the PDE4D short isoform, PDE4D2, enhanced the proliferation of cancer cells both in vitro and in vivo. Moreover, treatmentofcancer cells withaunique specific PDE4D inhibitor, 26B, triggered massive cell death and growth retardation. Notably, these antineoplastic effects induced by either shRNAs or small molecule occurred preferentially in cancer cells but not in nonmalignant epithelial cells. These results suggest that although targeted by genomic homozygous microdeletions, PDE4D functions as a tumor-promoting factor and represents a unique targetable enzyme of cancer cells.

著录项

  • 来源
  • 作者单位

    Women's Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, United States;

    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, United States;

    Santa Monica University of California-Los Angeles, Medical Center, Los Angeles, CA 90404, United StatesNational Institutes of Health (NIH), Chemical Genomics Center, National Center for Advancing Translational Sciences, NIH, Bethesda, MD 20892, United StatesNational University Cancer Institute, National University Hospital, Singapore 117599, SingaporeBasic Science Program, SAIC-Frederick, Inc., Chemical Biology Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, United StatesKey Laboratory of Malignant Tumor Gene Regulation and Target Therapy, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, ChinaDivision of Hematology/Oncology, Cedars-Sinai Medical Center, University of California, Los Angeles, CA 90048, United StatesCancer Science Institute of Singapore, National University of Singapore, Singapore 117599, SingaporeCharles R. Drew University of Medicine and Science, Los Angeles, CA 90059, United States;

  • 收录信息 美国《科学引文索引》(SCI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 英语
  • 中图分类 自然科学总论;
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号